Plain language answers to the questions we hear most, about the science and about where Rescue Bio stands today.
A personalized cancer vaccine is manufactured specifically for one patient, based on the unique mutations found in their own tumor. Unlike a traditional vaccine that trains the immune system against an external pathogen, a cancer vaccine trains the immune system to recognize and attack cells carrying the patient's own tumor specific mutations, called neoantigens.
A neoantigen is a small protein fragment, or peptide, produced by a mutation that exists only in a patient's tumor cells, not in their healthy tissue. Because it is genuinely foreign to the body's own cells, a neoantigen is a plausible target for the immune system to attack without harming healthy tissue.
Chemotherapy and most targeted therapies attack cancer cells directly. Immunotherapy, such as checkpoint inhibitors, removes brakes on the immune system generally. A personalized cancer vaccine does something different. It specifically teaches the immune system to recognize a patient's own tumor mutations, aiming for a targeted, durable response rather than a general one.
All three are different delivery mechanisms for teaching the immune system to recognize the same kind of target, a tumor specific neoantigen. A peptide vaccine delivers the target protein fragment directly. A DNA or mRNA vaccine instead delivers genetic instructions that a patient's own cells use to produce that target protein internally. See our Evidence page for real trial results across all three approaches.
Cancer vaccines are still an active area of clinical research, and the field has made real progress. Strong immune responses are achievable, as shown across many trials, and some have produced durable results as well. What has been harder to achieve consistently is durable clinical benefit tied to picking the right targets. In one of the most closely watched personalized vaccine trials, Mount Sinai's PGV001 in New York, 100 percent of patients developed a targeted immune response, but only 44 percent of the individual peptides administered actually triggered a T cell response. Better target selection is one of the field's central open problems.
NSP, short for Neoantigen Selection Platform, is Rescue Bio's target selection engine. Most existing approaches score candidate neoantigens mainly on binding affinity and gene expression. NSP adds a layer that weights candidates by whether the mutation is present in a tumor's stem-like, treatment resistant cell population, a bet on preventing relapse rather than only shrinking the visible tumor. See The Science for the full pipeline.
NSP scores every candidate mutation across several independent dimensions: binding strength, immune visibility, whether the tumor still expresses the machinery needed to present it, whether the relevant chromosome region has been lost, and manufacturability. It then assembles a final, capped set of peptides with an explicit, logged reason for every candidate that did not make the cut. A qualified human reviewer signs off before anything moves toward manufacturing.
Not yet. As of today, there is no confirmed Canadian clinician or treatment site, no confirmed launch date, and the regulatory process described above has not concluded. This page will be updated as that changes.
The company's initial focus is glioblastoma and pancreatic cancer, both essentially incurable once standard therapy is exhausted, with plans to expand into breast, renal and ovarian cancers.
Reach out through our Contact page. We are happy to answer questions from patients, families, clinicians or potential partners directly.
Reach out through our Contact page.